Krensavage Asset Management, LLC Next Cure, Inc. Transaction History

Krensavage Asset Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$2.72 - $5.19 $813 - $1,551	299 Added 0.96%	31,298 $86,000
Q2 2022 Aug 16, 2022	BUY	$3.38 - $5.27 $1,379 - $2,150	408 Added 1.33%	30,999 $146,000
Q1 2022 May 17, 2022	SELL	$4.76 - $6.24 $2,075 - $2,720	-436 Reduced 1.41%	30,591 $149,000
Q4 2021 Feb 15, 2022	BUY	$5.7 - $9.1 $570 - $910	100 Added 0.32%	31,027 $186,000
Q3 2021 Nov 16, 2021	SELL	$6.74 - $8.02 $2,884 - $3,432	-428 Reduced 1.37%	30,927 $208,000
Q2 2021 Aug 13, 2021	BUY	$7.6 - $10.28 $5,715 - $7,730	752 Added 2.46%	31,355 $252,000
Q1 2021 May 18, 2021	SELL	$9.81 - $13.88 $297,164 - $420,452	-30,292 Closed	0 $0
Q4 2020 Feb 17, 2021	BUY	$9.47 - $12.43 $286,865 - $376,529	30,292 New	30,292 $330,000

15.9M

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $26.9M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

Get notified when there are updates to the investment portfolio of Krensavage Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Krensavage Asset Management, LLC with notifications on news.